Form 4: Astera Labs Director Manuel Alba Sells Shares Under 10b5-1 Plan

Director Manuel Alba of Astera Labs sold a total of 10,900 shares of common stock on December 4, 2024, through a pre-arranged 10b5-1 trading plan.

Summary

• Manuel Alba, a director at Astera Labs, sold 10,900 shares of common stock on December 4, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 31, 2024.
• The shares were sold in multiple transactions at varying prices, ranging from $115.1300 to $121.05.
• The sales were made through various entities including Casa Alameda 2007, LLC and the Alba Trust.
• Following the transactions, Mr. Alba still indirectly owns a significant number of shares through these entities and his spouse.

Sentiment

Score: 5

Explanation: The document reflects a routine insider stock sale under a pre-arranged plan, which is neither particularly positive nor negative. It is a neutral event.

Risks

• The sales by a director could be perceived negatively by some investors, potentially impacting the stock price.
• The reliance on a 10b5-1 plan suggests a pre-determined strategy for selling shares, which could continue in the future.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives and directors to use 10b5-1 plans to manage their stock sales, which helps avoid accusations of trading on non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among corporate insiders to manage their stock sales.
• The reported transactions are consistent with typical Form 4 filings for directors selling shares.
• The price range of the sales is within the normal fluctuations of the stock price.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, but the pre-planned nature of the sales should mitigate concerns.

Key Dates

Keywords

Astera Labs, Manuel Alba, insider trading, Form 4, stock sale, Rule 10b5-1, director, ALAB